Virtuozzo’s Mature Linux Distribution VzLinux Now Available to Public
Virtuozzo, a global leader in high-efficiency virtualization and hyperconverged software solutions, today released its latest VzLinux operating system (VzLinux 8) to the general public. VzLinux - an enterprise distribution - has been used by Virtuozzo as a base OS for the company’s OpenVZ virtualization solution and other commercial products as well as a guest OS for more than 20 years. Web hosting service providers and other end customers deploying the technology gain the immediate benefits of a stable, long-term supported Linux distro maintained by the open-source community.
VzLinux 8 is a free, multi-purpose distro optimized to run in containers, virtual machines or on bare-metal servers. It is designed to support I/O-intensive, enterprise-level applications and workloads. Virtuozzo currently offers a ready-to-use utility to convert from CentOS 8 without downtime as well as templates for hyperscalers, enabling customers to deploy VzLinux 8 as a guest OS under various hypervisors. The conversion utility enables seamless conversions of CentOS 8 bare-metal servers, virtual machines and containers, effectively managing risk while minimizing negative business impact. Regarding containers, Virtuozzo provides advanced functionality including conversion dry-run, snapshot creation to roll back and unattended mass conversion. Options to convert from CentOS 7 will be made available in a future update.
Notably, VzLinux is a 1:1 binary compatible fork of Red Hat® Enterprise Linux®—specifically RHEL 8.
“The enterprise Linux distribution market is shifting away from CentOS-dominated Linux servers given the distro’s slated sunset later this year,” said Maik Broemme, Senior Product Manager, Virtuozzo. “The resulting gap in the market requires a reliable solution with longevity, which is why we opted to make our VzLinux publicly available. We simply aim to give the industry a viable, free alternative with seamless transition capabilities.”
Virtuozzo has a long history of sponsoring and contributing to well-known open-source projects such as OpenVZ, KVM, Docker, OpenStack, CRIU. The company’s confidence in its VzLinux distro has led to an in-house conversion of more than 200+ CentOS servers, ensuring Virtuozzo’s infrastructure is future-proofed well beyond December 2021 when CentOS is slated for end-of-life.
To download VzLinux 8 and for contributions to the VzLinux project, visit www.vzLinux.org.
About Virtuozzo
Virtuozzo is a leading, global provider of hybrid virtualization, storage and cloud enablement software solutions. The company’s software-defined, hyperconverged self-service platform and resource management capabilities enable hosting and service providers to provide end-customers with public and private cloud services. Virtuozzo is an industry pioneer who developed the first commercially available container technology 21 years ago. The company provides software solutions and services to over 450 service providers, ISVs, and enterprises worldwide to enable over 500 thousand virtual environments, running mission-critical cloud workloads. A significant force in the opensource community, Virtuozzo sponsors and/or is a contributor to numerous open-source projects including KVM, Docker, OpenStack, OpenVZ, CRIU and the Linux kernel. Learn more www.virtuozzo.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005356/en/
Contact information
Heather Ailara
211 Communications
+1.973.567.6040
heather@211comms.com
Christine Brunelli
Virtuozzo
+1 215-847-7842
christine.brunelli@virtuozzo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom